In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP
- 1 October 1996
- journal article
- Published by Elsevier in Immunopharmacology
- Vol. 35 (1), 53-63
- https://doi.org/10.1016/0162-3109(96)00123-3
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Secondary loss of deoxyguanosine kinase activity in purine nucleoside phosphorylase deficient miceBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1994
- Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate MofetilImmunological Reviews, 1993
- Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(Arylmethyl) derivatives of 9-deazaguanineJournal of Medicinal Chemistry, 1993
- Inhibition of the enzyme purine nucleoside phosphorylase (PNP) reduces refractoriness to transfused platelets in a dog modelBritish Journal of Haematology, 1990
- Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitorInflammation Research, 1987
- Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency.Archives of Disease in Childhood, 1987
- PROLONGATION OF SKIN GRAFT SURVIVAL IN DOGS TREATED WITH 8-AMINOGUANOSINETransplantation, 1986
- Allosteric regulation of calf thymus ribonucleoside diphosphate reductaseBiochemistry, 1979
- Deoxyguanosine toxicity on lymphoid cells as a cause for immunosuppression in purine nucleoside phosphorylase deficiencyCell, 1978
- Purine Nucleoside Phosphorylase Deficiency: Altered Kinetic Properties of a Mutant EnzymeScience, 1977